Current Rheumatology Reports

, Volume 8, Issue 4, pp 303–311

Wegener’s granulomatosis: Is biologic therapy useful?

  • Pasha Sarraf
  • Jonathan Kay
  • Robert P. Friday
  • Anthony M. Reginato
Article

DOI: 10.1007/s11926-006-0014-6

Cite this article as:
Sarraf, P., Kay, J., Friday, R.P. et al. Curr Rheumatol Rep (2006) 8: 303. doi:10.1007/s11926-006-0014-6

Abstract

Wegener’s granulomatosis (WG) is a complex autoimmune disorder that has been transformed from a uniformly lethal process to a chronic disease with a relapsingremitting course. In the setting of frequent relapses, the need to manage cumulative disease damage and drug toxicities has spurred the identification and development of new potent and directed therapies. Biologic agents, which offer the potential for remission-induction and drug-sparing approaches to treat WG, have been studied in several small, open-label clinical series and one large, randomized, placebo-controlled clinical trial. This article discusses the results of these trials and the potential of these biologic agents to treat WG.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Pasha Sarraf
  • Jonathan Kay
  • Robert P. Friday
  • Anthony M. Reginato
    • 1
  1. 1.Division of Rheumatology, Allergy and Immunology, Department of Internal MedicineMassachusetts General HospitalBostonUSA

Personalised recommendations